LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 46

Search options

  1. Article ; Online: Sobre los bomberos a los que les daba miedo el fuego.

    Villar-García, Judit

    Archivos de prevencion de riesgos laborales

    2022  Volume 25, Issue 2, Page(s) 80–85

    Title translation About Firefighters Who Were Afraid of Fire.
    MeSH term(s) Firefighters ; Fires ; Humans ; Occupational Exposure
    Language Spanish
    Publishing date 2022-04-15
    Publishing country Spain
    Document type Editorial
    ZDB-ID 2682372-X
    ISSN 1578-2549 ; 1578-2549
    ISSN (online) 1578-2549
    ISSN 1578-2549
    DOI 10.12961/aprl.2022.25.02.01
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Hepatic inflammatory pseudotumours mimicking metastatic disease in a non-HIV patient with secondary syphilis.

    Planella-Fontanillas, Nidia / Rial-Villavecchia, Abora / Villar-García, Judit / Parra-Navarro, Laura / Santiago-Díaz, Pablo / Pujol, Ramon M / Rodríguez-Morera, Jaime

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2024  

    Language English
    Publishing date 2024-02-10
    Publishing country England
    Document type Letter
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.19847
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.

    Knobel, Hernando / Cañas-Ruano, Esperanza / Guelar, Ana / Knobel, Pablo / Villar-García, Judit / González-Mena, Alicia / Canepa, Ceclia / Arrieta-Aldea, Itziar / Marcos, Augustin / Abalat-Torrres, Agustí / Güerri-Fernández, Roberto

    HIV research & clinical practice

    2023  Volume 24, Issue 1, Page(s) 2239564

    Abstract: Background: This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH).: Methods: The ... ...

    Abstract Background: This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH).
    Methods: The retrospective study conducted from April 2019 to November 2022, included PLWH with < 50 copies/mL of HIV-RNA prior to recruitment who initiated either D/L or B/F/T switching therapy. The primary objective was to evaluate treatment discontinuation rates; safety and virologic outcomes were also evaluated.
    Results: 690 PLWH were included, 358 in the D/L and 332 in the B/F/T, and a median follow-up of 728 and 1013 days, respectively. The discontinuation proportions were 8.7% (31 participants, incidence rate of 4.44 per 100 PYFU in the D/L group and 15.3% (51 participants, incidence rate of 6.25 per 100 PYFU) in the B/F/T group. The adjusted hazard ratio for B/F/T discontinuation compared to D/L was 1.20 (95% CI: 0.71;2.0;
    Conclusions: Switching to either B/T/F or D/L treatment for PLWH was effective and well tolerated in this real-world study. Treatment discontinuation rates did not significantly differ between the two regimens.
    MeSH term(s) Humans ; Lamivudine/adverse effects ; HIV Infections/drug therapy ; Retrospective Studies ; Adenine ; Treatment Outcome ; Emtricitabine ; Drug Combinations ; Heterocyclic Compounds, 4 or More Rings/adverse effects
    Chemical Substances tenofovir alafenamide (EL9943AG5J) ; Lamivudine (2T8Q726O95) ; dolutegravir (DKO1W9H7M1) ; bictegravir (8GB79LOJ07) ; Adenine (JAC85A2161) ; Emtricitabine (G70B4ETF4S) ; Drug Combinations ; Heterocyclic Compounds, 4 or More Rings
    Language English
    Publishing date 2023-07-26
    Publishing country England
    Document type Journal Article
    ISSN 2578-7470
    ISSN (online) 2578-7470
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism in SARS-CoV-2.

    Caguana-Vélez, Oswaldo Antonio / Khilzi, Karys / Piccari, Lucilla / Rodríguez-Sevilla, Juan Jose / Badenes-Bonet, Diana / Gonzalez-Garcia, Jose / Chalela, Roberto / Arita, Mariela / Rodó-Pin, Anna / Herranz, Anna / Admetlló, Mireia / Villar-Garcia, Judit / Molina, Lluis / Zuccarino, Flavio / Gea, Joaquin / Balcells, Eva / Rodríguez-Chiaradia, Diego A

    Respiration; international review of thoracic diseases

    2024  Volume 103, Issue 2, Page(s) 79–87

    Abstract: Introduction: Chronic thromboembolic pulmonary disease (CTEPD) consists of persistent pulmonary vascular obstruction on imaging and involves long-term functional limitations, with or without chronic thromboembolic pulmonary hypertension (CTEPH). The aim ...

    Abstract Introduction: Chronic thromboembolic pulmonary disease (CTEPD) consists of persistent pulmonary vascular obstruction on imaging and involves long-term functional limitations, with or without chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to evaluate the incidence and risk factors of both persistent pulmonary vascular defects and CTEPH after hospitalization in patients with COVID-19 and PE during a 2-year follow-up.
    Methods: A prospective observational study was carried out in a tertiary hospital center. Patients were hospitalized between March 2020 and December 2021 with a diagnosis of PE during SARS-CoV-2 infection. Patients received anticoagulant treatment for at least 3 months and were followed up for 2 years. Between the third and fourth months after discharge, all patients were evaluated for the presence of residual thrombotic defects by CTPA and/or perfusion pulmonary scintigraphy. Clinical findings, lung function tests with DLCO, exercise capacity, and echocardiograms were also assessed.
    Results: Of the 133 patients included, 18% had persistent thrombotic defects on lung imaging at follow-up. The incidence of CTEPD was 0.75% at 2 years of follow-up. Patients with persistent defects were significantly older, had a higher prevalence of systemic arterial hypertension, higher D-dimer and NT-proBNP levels, and more severe PE at diagnosis. Furthermore, there was a higher prevalence of right ventricular dysfunction on echocardiogram at diagnosis of PE (25.0% vs. 2.7%, p = 0.006). This was the only variable independently related to persistent defects in multivariate analyses (OR: 8.13 [95% CI: 1.82-36.32], p = 0.006).
    Conclusion: The persistence of thrombotic defects after PE is a common finding after SARS-CoV-2 infection, affecting 18% of the population. However, the incidence of CTEPH appears to be lower (0.75%) in COVID-19-related PE compared to that previously observed in PE unrelated to COVID-19.
    MeSH term(s) Humans ; Chronic Disease ; COVID-19/complications ; Hypertension, Pulmonary/epidemiology ; Hypertension, Pulmonary/etiology ; Hypertension, Pulmonary/diagnosis ; Lung ; Pulmonary Embolism/diagnostic imaging ; Pulmonary Embolism/epidemiology ; Pulmonary Embolism/etiology ; SARS-CoV-2 ; Thromboembolism/complications ; Prospective Studies
    Language English
    Publishing date 2024-02-07
    Publishing country Switzerland
    Document type Observational Study ; Journal Article
    ZDB-ID 206674-9
    ISSN 1423-0356 ; 0025-7931
    ISSN (online) 1423-0356
    ISSN 0025-7931
    DOI 10.1159/000536064
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Individual blood concentrations of persistent organic pollutants and chemical elements, and COVID-19: A prospective cohort study in Barcelona.

    Porta, Miquel / Pumarega, José / Gasull, Magda / Aguilar, Ruth / Henríquez-Hernández, Luis A / Basagaña, Xavier / Zumbado, Manuel / Villar-García, Judit / Rius, Cristina / Mehta, Sneha / Vidal, Marta / Jimenez, Alfons / Campi, Laura / Lop, Joan / Pérez Luzardo, Octavio L / Dobaño, Carlota / Moncunill, Gemma

    Environmental research

    2023  Volume 223, Page(s) 115419

    Abstract: Background: There is wide, largely unexplained heterogeneity in immunological and clinical responses to SARS-CoV-2 infection. Numerous environmental chemicals, such as persistent organic pollutants (POPs) and chemical elements (including some metals, ... ...

    Abstract Background: There is wide, largely unexplained heterogeneity in immunological and clinical responses to SARS-CoV-2 infection. Numerous environmental chemicals, such as persistent organic pollutants (POPs) and chemical elements (including some metals, essential trace elements, rare earth elements, and minority elements), are immunomodulatory and cause a range of adverse clinical events. There are no prospective studies on the effects of such substances on the incidence of SARS-CoV-2 infection and COVID-19.
    Objective: To investigate the influence of blood concentrations of POPs and elements measured several years before the pandemic on the development of SARS-CoV-2 infection and COVID-19 in individuals from the general population.
    Methods: We conducted a prospective cohort study in 154 individuals from the general population of Barcelona. POPs and elements were measured in blood samples collected in 2016-2017. SARS-CoV-2 infection was detected by rRT-PCR in nasopharyngeal swabs and/or by antibody serology using eighteen isotype-antigen combinations measured in blood samples collected in 2020-2021. We analyzed the associations between concentrations of the contaminants and SARS-CoV-2 infection and development of COVID-19, taking into account personal habits and living conditions during the pandemic.
    Results: Several historically prevalent POPs, as well as arsenic, cadmium, mercury, and zinc, were not associated with COVID-19, nor with SARS-CoV-2 infection. However, DDE (adjusted OR = 5.0 [95% CI: 1.2-21]), lead (3.9 [1.0-15]), thallium (3.4 [1.0-11]), and ruthenium (5.0 [1.8-14]) were associated with COVID-19, as were tantalum, benzo(b)fluoranthene, DDD, and manganese. Thallium (3.8 [1.6-8.9]), and ruthenium (2.9 [1.3-6.7]) were associated with SARS-CoV-2 infection, and so were lead, gold, and (protectively) iron and selenium. We identified mixtures of up to five substances from several chemical groups, with all substances independently associated to the outcomes.
    Conclusions: Our results provide the first prospective and population-based evidence of an association between individual concentrations of some contaminants and COVID-19 and SARS-CoV-2 infection. POPs and elements may contribute to explain the heterogeneity in the development of SARS-CoV-2 infection and COVID-19 in the general population. If the associations are confirmed as causal, means are available to mitigate the corresponding risks.
    MeSH term(s) Humans ; COVID-19/epidemiology ; Persistent Organic Pollutants ; SARS-CoV-2 ; Prospective Studies ; Ruthenium ; Thallium ; Environmental Pollutants
    Chemical Substances Persistent Organic Pollutants ; Ruthenium (7UI0TKC3U5) ; Thallium (AD84R52XLF) ; Environmental Pollutants
    Language English
    Publishing date 2023-02-04
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 205699-9
    ISSN 1096-0953 ; 0013-9351
    ISSN (online) 1096-0953
    ISSN 0013-9351
    DOI 10.1016/j.envres.2023.115419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Prepandemic personal concentrations of per- and polyfluoroalkyl substances (PFAS) and other pollutants: Specific and combined effects on the incidence of COVID-19 disease and SARS-CoV-2 infection.

    Pumarega, José / Gasull, Magda / Koponen, Jani / Campi, Laura / Rantakokko, Panu / Henríquez-Hernández, Luis A / Aguilar, Ruth / Donat-Vargas, Carolina / Zumbado, Manuel / Villar-García, Judit / Rius, Cristina / Santiago-Díaz, Pablo / Vidal, Marta / Jimenez, Alfons / Iglesias, Mar / Dobaño, Carlota / Moncunill, Gemma / Porta, Miquel

    Environmental research

    2023  Volume 237, Issue Pt 2, Page(s) 116965

    Abstract: Objective: To investigate the specific and combined effects of personal concentrations of some per- and polyfluoroalkyl substances (PFAS), other persistent organic pollutants (POPs), and chemical elements -measured in individuals' blood several years ... ...

    Abstract Objective: To investigate the specific and combined effects of personal concentrations of some per- and polyfluoroalkyl substances (PFAS), other persistent organic pollutants (POPs), and chemical elements -measured in individuals' blood several years before the pandemic- on the development of SARS-CoV-2 infection and COVID-19 disease in the general population.
    Methods: We conducted a prospective cohort study in 240 individuals from the general population of Barcelona. PFAS, other POPs, and chemical elements were measured in plasma, serum, and whole blood samples, respectively, collected in 2016-2017. PFAS were analyzed by liquid chromatography-triple quadrupole mass spectrometry. SARS-CoV-2 infection was detected by rRT-PCR in nasopharyngeal swabs and/or antibody serology in blood samples collected in 2020-2021.
    Results: No individual PFAS nor their mixtures were significantly associated with SARS-CoV-2 seropositivity or COVID-19 disease. Previously identified mixtures of POPs and elements (Porta et al., 2023) remained significantly associated with seropositivity and COVID-19 when adjusted for PFAS (all OR > 4 or p < 0.05). Nine chemicals comprised mixtures associated with COVID-19: thallium, ruthenium, lead, benzo[b]fluoranthene, DDD, other DDT-related compounds, manganese, tantalum, and aluminium. And nine chemicals comprised the mixtures more consistently associated with SARS-CoV-2 seropositivity: thallium, ruthenium, lead, benzo[b]fluoranthene, DDD, gold, and (protectively) selenium, indium, and iron.
    Conclusions: The PFAS studied were not associated with SARS-CoV-2 seropositivity or COVID-19. The results confirm the associations between personal blood concentrations of some POPs and chemical elements and the risk of COVID-19 and SARS-CoV-2 infection in what remains the only prospective and population-based cohort study on the topic. Mixtures of POPs and chemical elements may contribute to explain the heterogeneity in the risks of SARS-CoV-2 infection and COVID-19 in the general population.
    Language English
    Publishing date 2023-08-29
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 205699-9
    ISSN 1096-0953 ; 0013-9351
    ISSN (online) 1096-0953
    ISSN 0013-9351
    DOI 10.1016/j.envres.2023.116965
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B-cell responses.

    de Campos-Mata, Leire / Tejedor Vaquero, Sonia / Tachó-Piñot, Roser / Piñero, Janet / Grasset, Emilie K / Arrieta Aldea, Itziar / Rodrigo Melero, Natalia / Carolis, Carlo / Horcajada, Juan P / Cerutti, Andrea / Villar-García, Judit / Magri, Giuliana

    Clinical & translational immunology

    2021  Volume 10, Issue 9, Page(s) e1339

    Abstract: Objectives: SARS-CoV-2 infection induces virus-reactive memory B cells expressing unmutated antibodies, which hints at their emergence from naïve B cells. Yet, the dynamics of virus-specific naïve B cells and their impact on immunity and immunopathology ...

    Abstract Objectives: SARS-CoV-2 infection induces virus-reactive memory B cells expressing unmutated antibodies, which hints at their emergence from naïve B cells. Yet, the dynamics of virus-specific naïve B cells and their impact on immunity and immunopathology remain unclear.
    Methods: We longitudinally profiled SARS-CoV-2-specific B-cell responses in 25 moderate-to-severe COVID-19 patients by high-dimensional flow cytometry and isotyping and subtyping ELISA. We also explored the relationship of B-cell responses to SARS-CoV-2 with the activation of effector and regulatory cells from the innate or adaptive immune system.
    Results: We found a virus-specific antibody response with a broad spectrum of classes and subclasses during acute infection, which evolved into an IgG1-dominated response during convalescence. Acute infection was associated with increased mature B-cell progenitors in the circulation and the unexpected expansion of virus-targeting naïve-like B cells. The latter further augmented during convalescence together with virus-specific memory B cells. In addition to a transitory increase in tissue-homing CXCR3
    Conclusion: Aside from providing new insights into the complexity of the immune response to SARS-CoV-2, our findings indicate that the
    Language English
    Publishing date 2021-09-05
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 2694482-0
    ISSN 2050-0068
    ISSN 2050-0068
    DOI 10.1002/cti2.1339
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.

    Santos, José Ramón / Casadellà, Maria / Noguera-Julian, Marc / Micán-Rivera, Rafael / Domingo, Pere / Antela, Antonio / Portilla, Joaquin / Sanz, Jesús / Montero-Alonso, Marta / Navarro, Jordi / Masiá, Mar / Valcarce-Pardeiro, Nieves / Ocampo, Antonio / Pérez-Martínez, Laura / García-Vallecillos, Coral / Vivancos, María Jesús / Imaz, Arkaitz / Iribarren, José Antonio / Hernández-Quero, José /
    Villar-García, Judit / Barrufet, Pilar / Paredes, Roger

    Frontiers in cellular and infection microbiology

    2023  Volume 13, Page(s) 1187999

    Abstract: Introduction: Second-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, ... ...

    Abstract Introduction: Second-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients.
    Methods: Real-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naïve patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) ≥200 copies/mL at 24 weeks or as a single determination of VL ≥1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated.
    Results: Virological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naïve patients with CD4+ nadir <100 cells/μL were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles.
    Discussion: Whereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available.
    MeSH term(s) Adult ; Humans ; Spain ; Prospective Studies ; Cobicistat ; Integrases ; HIV Infections/drug therapy
    Chemical Substances Cobicistat (LW2E03M5PG) ; Integrases (EC 2.7.7.-)
    Language English
    Publishing date 2023-06-26
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2619676-1
    ISSN 2235-2988 ; 2235-2988
    ISSN (online) 2235-2988
    ISSN 2235-2988
    DOI 10.3389/fcimb.2023.1187999
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19.

    Badenes Bonet, Diana / Caguana Vélez, Oswaldo Antonio / Duran Jordà, Xavier / Comas Serrano, Merce / Posso Rivera, Margarita / Admetlló, Mireia / Herranz Blasco, Anna / Cuadrado Godia, Elisa / Marco Navarro, Ester / Martin Ezquerra, Gemma / Pineiro Aguin, Zenaida / Cumpli Gargallo, Maria Cinta / Gonzalez Garcia, Jose Gregorio / Balcells Vilarnau, Eva / Rodriguez Chiaradia, Diego / Castells, Xavier / Gea, Joaquim / Horcajada, Juan P / Villar-García, Judit

    Journal of clinical medicine

    2023  Volume 12, Issue 12

    Abstract: Background: The post-acute sequelae of SARS-CoV-2 (PASC) infection have caused a significant impact on our health system, but there is limited evidence of approved drugs focused on its prevention. Our objective was to identify risk factors that can ... ...

    Abstract Background: The post-acute sequelae of SARS-CoV-2 (PASC) infection have caused a significant impact on our health system, but there is limited evidence of approved drugs focused on its prevention. Our objective was to identify risk factors that can determine the presence of PASC, with special attention to the treatment received in the acute phase, and to describe the profile of persistent symptoms in a multidisciplinary Post-Coronavirus Disease-19 (COVID-19) Unit.
    Methods: This one-year prospective observational study included patients following an acute COVID-19 infection, irrespective of whether they required hospital admission. A standardized symptom questionnaire and blood sampling were performed at the first follow-up visit, and demographic and clinical electronic data were collected. We compared subjects with PASC with those who had fully recovered. Multivariate logistic regression was performed to identify factors associated with PASC in hospitalized patients, and Kaplan-Meier curves were used to assess duration of symptoms according to disease severity and treatments received in the acute phase.
    Results: 1966 patients were evaluated; 1081 had mild disease, 542 moderate and 343 severe; around one third of the subjects had PASC, and were more frequently female, with obesity, asthma, and eosinophilia during acute COVID-19 disease. Patients who received treatment with dexamethasone and remdesivir during the course of the acute illness showed a lower median duration of symptoms, compared with those who received none of these treatments.
    Conclusion: Treatment with dexamethasone and/or remdesivir may be useful to reduce the impact of PASC secondary to SARS-CoV-2 infection. In addition, we identified female gender, obesity, asthma, and disease severity as risk factors for having PASC.
    Language English
    Publishing date 2023-06-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12124158
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Calcifediol Treatment and COVID-19-Related Outcomes.

    Nogues, Xavier / Ovejero, Diana / Pineda-Moncusí, Marta / Bouillon, Roger / Arenas, Dolors / Pascual, Julio / Ribes, Anna / Guerri-Fernandez, Robert / Villar-Garcia, Judit / Rial, Abora / Gimenez-Argente, Carme / Cos, Maria Lourdes / Rodriguez-Morera, Jaime / Campodarve, Isabel / Quesada-Gomez, José Manuel / Garcia-Giralt, Natalia

    The Journal of clinical endocrinology and metabolism

    2021  Volume 106, Issue 10, Page(s) e4017–e4027

    Abstract: Context: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity.: Objective: This work aims to elucidate the effect of ... ...

    Abstract Context: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity.
    Objective: This work aims to elucidate the effect of 25(OH)D3 (calcifediol) treatment on COVID-19-related outcomes.
    Methods: This observational cohort study was conducted from March to May 2020, among patients admitted to COVID-19 wards of Hospital del Mar, Barcelona, Spain. A total of 930 patients with COVID-19 were included; 92 were excluded because of previous calcifediol intake. Of the remaining 838, a total of 447 received calcifediol (532 μg on day 1 plus 266 μg on days 3, 7, 15, and 30), whereas 391 were not treated at the time of hospital admission (intention-to-treat). Of the latter, 53 patients were treated later during ICU admission and were allocated in the treated group in a second analysis. In healthy individuals, calcifediol is about 3.2-fold more potent on a weight basis than cholecalciferol. Main outcome measures were ICU admission and mortality.
    Results: ICU assistance was required by 102 (12.2%) participants. Out of 447 patients treated with calcifediol at admission, 20 (4.5%) required the ICU, compared to 82 (21%) out of 391 nontreated (P < .001). Logistic regression of calcifediol treatment on ICU admission, adjusted by age, sex, linearized 25-hydroxyvitamin D levels at baseline, and comorbidities showed that treated patients had a reduced risk of requiring the ICU (odds ratio [OR] 0.13; 95% CI 0.07-0.23). Overall mortality was 10%. In the intention-to-treat analysis, 21 (4.7%) out of 447 patients treated with calcifediol at admission died compared to 62 patients (15.9%) out of 391 nontreated (P = .001). Adjusted results showed a reduced mortality risk with an OR of 0.21 (95% CI, 0.10-0.43). In the second analysis, the obtained OR was 0.52 (95% CI, 0.27-0.99).
    Conclusion: In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality.
    MeSH term(s) Adult ; Aged ; COVID-19/blood ; COVID-19/drug therapy ; COVID-19/epidemiology ; Calcifediol/administration & dosage ; Cholecalciferol/administration & dosage ; Cohort Studies ; Comorbidity ; Female ; Hospital Mortality ; Hospitalization ; Humans ; Intensive Care Units ; Male ; Middle Aged ; SARS-CoV-2 ; Spain ; Treatment Outcome ; Vitamin D/analogs & derivatives ; Vitamin D/blood ; Vitamin D Deficiency/blood ; Vitamin D Deficiency/complications ; Vitamin D Deficiency/epidemiology
    Chemical Substances Vitamin D (1406-16-2) ; Cholecalciferol (1C6V77QF41) ; 25-hydroxyvitamin D (A288AR3C9H) ; Calcifediol (P6YZ13C99Q)
    Language English
    Publishing date 2021-06-21
    Publishing country United States
    Document type Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgab405
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top